ArticleJAMA network open2023

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.

Rachel S Goodman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.